Meyer Handelman Company’s Elicio Therapeutics ELTX Stock Holding History

Meyer Handelman Company’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54.3K	Hold	13,899	–	–	﹤0.01%	272
2026 Q1	$149K	Hold	13,899	–	–	﹤0.01%	218
2025 Q4	$111K	Hold	13,899	–	–	﹤0.01%	213
2025 Q3	$152K	Hold	13,899	–	–	﹤0.01%	213
2025 Q2	$107K	Hold	13,899	–	–	﹤0.01%	215
2025 Q1	$85.6K	Hold	13,899	–	–	﹤0.01%	212
2024 Q4	$70.9K	Hold	13,899	–	–	﹤0.01%	210
2024 Q3	$69.9K	Hold	13,899	–	–	﹤0.01%	212
2024 Q2	$57.1K	Hold	13,899	–	–	﹤0.01%	205
2024 Q1	$106K	Hold	13,899	–	–	﹤0.01%	201
2023 Q4	$116K	Hold	13,899	–	–	﹤0.01%	188
2023 Q3	$117K	Buy	13,899 +661	+5%	+$6.29K	﹤0.01%	188
2023 Q2	$126K	Buy	+13,238	New	+$121K	0.01%	183

Other funds holding ELTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Meyer Handelman Company's ELTX Position: Q2 2026 in Review

Meyer Handelman Company held its Elicio Therapeutics (ELTX) position steady in Q2 2026 at 13,899 shares worth $54.3K. The position accounts for ﹤0.01% of the portfolio, ranked #272.

Meyer Handelman Company first reported a position in ELTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $152K in Q3 2025. 46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Meyer Handelman Company held 13,899 shares of Elicio Therapeutics worth $54.3K as of Q2 2026.
Meyer Handelman Company left its Elicio Therapeutics share count unchanged in Q2 2026.
Elicio Therapeutics made up ﹤0.01% of Meyer Handelman Company's portfolio in Q2 2026, its #272 holding.
Meyer Handelman Company first reported a position in Elicio Therapeutics in Q2 2023 and has held it in 13 quarters since.
Meyer Handelman Company's Elicio Therapeutics position peaked at $152K in Q3 2025.
46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Meyer Handelman Company's 13F filing for Q2 2026, filed 3 Aug 2026.